(Source: American College of Cardiology Foundation) Background Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for the development of atherosclerotic disease. Statin therapy reduces LDL-C and cardiovascular events in patients with or without cardiovascular disease. Previous studies have shown an increased incidence of diabetes with statin therapy.1 Additionally, high-dose statin therapy has been associated with a greater risk of new-onset diabetes compared with a moderate-intensity statin.2 In a large randomized trial of patients with recent acute coronary syndrome, ezetimibe, a non-statin lipid-lowering drug that decreases intestinal absorption of cholesterol, added to...
↧